Mylan News Baked In
Mylan N.V. (MYL) is a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector.
.below_low_valuation { background: #2CC822; color: #fff; font-weight: bold; } .low_valuation_5 { background: #BFF2AB; color: #000; font-weight: bold; } .above_high_valuation { background: #D21614; color: #fff; font-weight: bold; } .high_valuation_5 { background: #F28264; color: #000; font-weight: bold; } .stockbox_table { color: #000000; border:none !important; font-family: 'open_sansregular'; }
.stockbox_shortcode_table td { text-align: center; vertical-align: middle; padding:5px !important; padding-right:10px !important; } .stockbox_shortcode_table td a{ color:#0066CC !important; text-decoration:none !important; } .stockbox_shortcode_table td a:hover{ color:#0066CC !important; text-decoration:none !important; font-weight:bold !important; } #stock_table_loading { color: #fff; margin-bottom: 5px; text-align: center; }
#stock_shortcode_table_us, #stock_shortcode_table_tsx { display:table-row-group; border-collapse: separate !important; border-spacing: 1px !important; font-size: 8px !important; line-height: 15px; }
.stockbox_shortcode h3 a { color: #A3CA52; }
.lgnd span { margin: 3px; padding: 3px; }
.stockbox_shortcode{ background-color:#7151b1; border-radius:6px; width:280px; float:right; margin:0px 10px 10px; } .stockbox_shortcode h3{ color:#fff !important; font-size:15px; padding:10px; padding-bottom:0px; margin: 15px 0px; }
.lgnd{ /*background-color:#e7e7e7;*/ /*border-radius: 0px 0px 6px 6px;*/ padding:10px; font-size: 10px; /*color: #000000;*/ }
.lgnd hr { margin-top: 5px; margin-bottom: 5px; border:0px; height: 1px; background: transparent; border-top: 1px solid #fff; } .widget_top_picks_stock_widget { list-style:none !important; }
var ajaxurl = 'https://purplechips.com/wp-admin/admin-ajax.php ' ;
function add_to_watchlist(company_name,storage_symbol,stock_exchange,user_id,attachobj) { jQuery.ajax({ type: 'POST', url: ajaxurl, data: { action : 'add_to_watchlist', ajax : 'true', type : "POST", companyname:company_name, storagesymbol:storage_symbol, stockexchange:stock_exchange, userid:user_id }, success: function(data, textStatus, XMLHttpRequest){ jQuery(attachobj).parent().find('img#add_to').attr('src','https://purplechips.com/wp-content/plugins/pc_graph_plugin/images//watch-icon.png'); jQuery(attachobj).parent().find('img#add_to').attr('title','Symbol Added to YOur Watchlist'); alert(data);
}, error: function(MLHttpRequest, textStatus, errorThrown){ alert(1);
} });
}
function displayGraph(symbol_value,symbol_exchange) {
displaySymbolGraph(symbol_value,symbol_exchange);
}
jQuery(document).ready( function() { jQuery('#stock_shortcode_table_us').fadeIn( function() { jQuery('#stock_shortcode_table_loading').fadeOut(); jQuery('#stock_shortcode_tab_us').css('font-weight', 'bold'); }); });
Feb 14, 2017, 9:28 am EDT Purple Chips Model Company Symbol Current Price Low Valuation High Valuation MYL $39.78 $37.00 $52.00
Mylan has been under pressure recently because regulators were scrutinizing a recently imposed price hike for the popular “EpiPen” which is familiar to anyone with severe allergic reactions.
We believe that the current valuation level at 9X earnings is more than discounting the risk of a drop in profitability for the Epipen. The Purple Chips 12 -18 month target is $56.00
LOW VALUATION IN MYLAN AT $40.56 (MYL-US) HALF POSITION
PURPLE CHIPS TARGET: $56.00 POSITION SIZE: HALF (2.5%) P/E: 8.8X DIV: NIL MKT CAP: $21B Debt: $6.3B NOPCF per share: 91% EARNINGS YIELD: 6.4% 5 YR EPS Growth rate*:10% P/E/G Ratio: 0.9X 2016 EPS: $4.57 2017 EST.: $5.76 2018 EST.: $6.13 *Blended growth rate= 2/3 historical (5yrs), 1/3 forward.
<!-- copy and paste indian viagra alternative. Modify height and width if desired. -->